Journals / Dicle Tıp Dergisi / 2026 / Cilt: 53 Sayı: 2

Resveratrol Modulates Apoptosis- and Cell Cycle-Related Gene Expression in Ishikawa Endometrial Cancer Cells

Resveratrol, Ishikawa Endometriyal Kanser Hücrelerinde Apoptoz ve Hücre Döngüsü ile İlişkili Gen Ekspresyonunu Modüle Eder

Oya Korkmaz(MALATYA TURGUT OZAL UNIVERSITY)
Pages
313–321
Publication Date
2026-06-05
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These results indicate that resveratrol promotes pro-apoptotic transcriptional responses and reduces cell viability, potentially associated with changes in genes related to estrogen receptor signaling and PTEN pathways.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The present study investigated the impact of resveratrol on cellular viability, apoptotic activity, proliferative capacity, and estrogen receptor/PTEN-associated signaling pathways in the ER-positive endometrial cancer cell line Ishikawa.
📊
Key Findings & Data:Methods: Ishikawa cells were treated with different concentrations of resveratrol, and cell viability was assessed at 24, 48, and 72 hours using the MTT test.
💡
Conclusion & Impact:Conclusion: These results indicate that resveratrol promotes pro-apoptotic transcriptional responses and reduces cell viability, potentially associated with changes in genes related to estrogen receptor signaling and PTEN pathways.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Endometriyal kanser · Resveratrol · Apoptoz

Abstract

Background: The present study investigated the impact of resveratrol on cellular viability, apoptotic activity, proliferative capacity, and estrogen receptor/PTEN-associated signaling pathways in the ER-positive endometrial cancer cell line Ishikawa. Methods: Ishikawa cells were treated with different concentrations of resveratrol, and cell viability was assessed at 24, 48, and 72 hours using the MTT test. Based on dose-response results, sub-cytotoxic doses (15 and 30 μM) were selected for molecular studies. mRNA expression of apoptosis-related genes (BAX, BCL-2, CASP3), the proliferation marker CCND1, estrogen receptor gene ESR1, and tumor suppressor PTEN was quantified using qRT-PCR. Results: Resveratrol treatment caused a progressive, dose- and time-dependent decrease in Ishikawa cell viability. qRT-PCR analysis demonstrated upregulation of pro-apoptotic BAX and CASP3, downregulation of anti-apoptotic BCL-2 and proliferation-associated CCND1, significant suppression of ESR1, and dose-dependent elevation of PTEN expression. An increased BAX/BCL-2 ratio indicates that cellular homeostasis has shifted towards a pro-apoptotic state. Conclusion: These results indicate that resveratrol promotes pro-apoptotic transcriptional responses and reduces cell viability, potentially associated with changes in genes related to estrogen receptor signaling and PTEN pathways. The observed effects at sub-cytotoxic concentrations suggest resveratrol as a promising candidate for experimental adjunct therapy in ER-positive endometrial cancer models.

Özet

Giriş: Bu çalışma, ER-pozitif endometriyal kanser hücre hattı Ishikawa’da resveratrolün hücre canlılığı, apoptoz, proliferasyon ve östrojen reseptörü/PTEN ile ilişkili yolaklar üzerindeki etkilerini incelemeyi amaçlamıştır. Yöntemler: Ishikawa hücrelerine farklı konsantrasyonlarda resveratrol uygulanmış ve hücre canlılığı 24, 48 ve 72 saatlerde MTT testi ile değerlendirilmiştir. Doz–yanıt sonuçlarına dayanarak moleküler analizler için sub-sitotoksik dozlar (15 ve 30 μM) seçilmiştir. Apoptoz ile ilişkili genlerin (BAX, BCL-2, CASP3), proliferasyon belirteci CCND1’in, östrojen reseptör geni ESR1’in ve tümör baskılayıcı PTEN’in mRNA ekspresyon düzeyleri qRT-PCR yöntemi kullanılarak kantitatif olarak belirlenmiştir. Bulgular: Resveratrol uygulaması Ishikawa hücre canlılığında doza ve zamana bağlı, progresif bir azalmaya yol açmıştır. qRT-PCR analizleri, pro-apoptotik BAX ve CASP3 genlerinde artış; anti-apoptotik BCL-2 ve proliferasyonla ilişkili CCND1 genlerinde azalma; ESR1 ekspresyonunda belirgin baskılanma ve PTEN ekspresyonunda doza bağlı artış olduğunu göstermiştir. Artmış BAX/BCL-2 oranı, hücresel dengenin pro-apoptotik yönde değiştiğini göstermektedir. Sonuç: Bu bulgular, resveratrolün pro-apoptotik transkripsiyonel yanıtları desteklediğini ve hücre canlılığını azalttığını; bu etkilerin östrojen reseptörü sinyallemesi ve PTEN ile ilişkili genlerde meydana gelen değişikliklerle ilişkili olabileceğini göstermektedir. Sub-sitotoksik konsantrasyonlarda gözlenen etkiler, resveratrolün ER-pozitif endometriyal kanser modellerinde deneysel adjuvan tedavi için umut verici bir aday olabileceğini düşündürmektedir.

🔖

Cite This Article

Korkmaz, O. (2026). Resveratrol Modulates Apoptosis- and Cell Cycle-Related Gene Expression in Ishikawa Endometrial Cancer Cells. Dicle Tıp Dergisi, Cilt: 53 Sayı: 2, 313–321. https://doi.org/10.5798/dicletip.1964292

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (31)

  1. Anca-Stanciu MB, Manu A, Olinca MV, et al.Comprehensive review of endometrial cancer: newmolecular and FIGO classification and recenttreatment changes. J Clin Med. 2025; 14: 1385.
  2. Agnew HJ, Baker-Rand H, Kitson SJ, Crosbie EJ.Leading causes of death after a diagnosis ofendometrial cancer: a systematic review and meta-analysis. Obstet Gynecol Surv. 2025; 80: 701-2.
  3. Onstad MA, Schmandt RE, Lu KH. Addressing therole of obesity in endometrial cancer risk,prevention, and treatment. J Clin Oncol. 2016; 34:4225-30.
  4. Setiawan VW, Yang HP, Pike MC, et al. Type I andII endometrial cancers: have they different riskfactors? J Clin Oncol. 2013; 31: 2607-18.
  5. Roncolato F, Lindemann K, Willson ML, et al.PI3K/AKT/mTOR inhibitors for advanced orrecurrent endometrial cancer. Cochrane DatabaseSyst Rev. 2019; 10: CD012160.
  6. Hu Y, Liu P, Rosen N, Jiang X. Targeting mTORC1to promote ferroptosis and apoptosis in endometrial cancer with PI3K-Akt-mTOR pathway mutation.Ferroptosis Oxid Stress. 2025; 1: 202504.
  7. Vidal-Sabanés M, Bonifaci N, Navaridas R, et al.Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503. Cell DeathDis. 2025; 16: 705.
  8. Vogler M, Braun Y, Smith VM, et al. The BCL2family: from apoptosis mechanisms to newadvances in targeted therapy. Signal TransductTarget Ther. 2025; 10: 91.
  9. Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. Therole of BCL-2 family proteins in regulating apoptosisand cancer therapy. Front Oncol. 2022; 12: 985363.
  10. Jeffreys SA, Becker TM, Khan S, et al. Prognosticand predictive value of CCND1/cyclin D1amplification in breast cancer with a focus onpostmenopausal patients: a systematic review andmeta-analysis. Front Endocrinol (Lausanne). 2022;13: 895729.
  11. Salehi B, Mishra AP, Nigam M, et al. Resveratrol:a double-edged sword in health benefits.Biomedicines. 2018; 6: 91.
  12. Liu Y, Tong L, Luo Y, Li X, Chen G, Wang Y.Resveratrol inhibits proliferation and inducesapoptosis in ovarian cancer cells via inhibition ofglycolysis and targeting the AMPK/mTOR signalingpathway. J Cell Biochem. 2018; 119: 6162-72.
  13. Qin X, Luo H, Deng Y, Yao X, Zhang J, He B.Resveratrol inhibits proliferation and inducesapoptosis via the Hippo/YAP pathway in humancolon cancer cells. Biochem Biophys Res Commun.2022; 636: 197-204.
  14. Poschner S, Maier-Salamon A, Zehl M, et al.Resveratrol inhibits key steps of steroid metabolism in a human estrogen receptor–positive breastcancer model: impact on cellular proliferation. Front Pharmacol. 2018; 9: 742.
  15. Qasem RJ. The estrogenic activity of resveratrol:a comprehensive review of in vitro and in vivoevidence and the potential for endocrine disruption.Crit Rev Toxicol. 2020; 50: 439-62.
  16. Fukuda T, Oda K, Wada-Hiraike O, et al.Autophagy inhibition augments resveratrol-inducedapoptosis in Ishikawa endometrial cancer cells.Oncol Lett. 2016; 12: 2560-6.
  17. Almatroodi SA, Alsahli MA, Aljohani ASM, et al.Potential therapeutic targets of resveratrol, a plantpolyphenol, and its role in the therapy of varioustypes of cancer. Molecules. 2022; 27: 2665.
  18. Fu X, Wang Y, Li M, et al. Targeting of cancer celldeath mechanisms by resveratrol: a review.Apoptosis. 2021; 26: 561-73.
  19. Kim SE, Shin SH, Lee JY, et al. Resveratrol induces mitochondrial apoptosis and inhibits epithelial–mesenchymal transition in oral squamous cellcarcinoma cells. Nutr Cancer. 2018; 70: 125-35.
  20. Juan ME, Wenzel U, Daniel H, Planas JM.Resveratrol induces apoptosis through ROS-dependent mitochondrial pathway in HT-29 humancolorectal carcinoma cells. J Agric Food Chem. 2008;56: 4813-8.
  21. Ma X, Tian X, Huang X, Yan F, Qiao D. Resveratrol-induced mitochondrial dysfunction and apoptosisare associated with Ca²⁺ and mCICR-mediated MPTactivation in HepG2 cells. Mol Cell Biochem. 2007;302: 99-109.
  22. Kumar S, Eroglu E, Stokes JA, et al. Resveratrolinduces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancercells. Oncotarget. 2017; 8: 20895-908.
  23. Atram MA, Shivkumar VB, Gangane NM.Immunohistochemical analysis of novel biomarkerscyclin D1, p53 and Ki67 in endometrial carcinoma:clinicopathological significance and prognosticvalue. Gulf J Oncol. 2022; 38: 15-23.
  24. Sangwan K, Garg M, Pathak N, Bharti L.Expression of cyclin D1 in hyperplasia andcarcinoma of endometrium and its correlation withhistologic grade, tumor type, and clinicopathologicalfeatures. J Lab Physicians. 2020; 12: 165-70.
  25. Ge Y, Ni X, Li J, Ye M, Jin X. Roles of estrogenreceptor alpha in endometrial carcinoma (review).Oncol Lett. 2023; 26: 530.
  26. Nwachukwu JC, Srinivasan S, Bruno NE, et al.Resveratrol modulates the inflammatory responsevia an estrogen receptor–signal integrationnetwork. eLife. 2014; 3: e02057.
  27. Kobylka P, Kucinska M, Kujawski J, et al.Resveratrol analogues as selective estrogensignaling pathway modulators: structure–activityrelationship. Molecules. 2022; 27: 6973.
  28. Lephart ED. Phytoestrogens (resveratrol andequol) for estrogen-deficient skin —controversies/misinformation versus anti-aging invitro and clinical evidence. Int J Mol Sci. 2021; 22:11218.
  29. Hameed JSF, Devarajan A, MSDP, et al. PTEN-negative endometrial cancer cells protect theirgenome through enhanced DDB2 expressionassociated with augmented nucleotide excisionrepair. BMC Cancer. 2023; 23: 399.
  30. Philip CA, Laskov I, Beauchamp MC, et al.Inhibition of PI3K–AKT–mTOR pathway sensitizesendometrial cancer cell lines to PARP inhibitors.BMC Cancer. 2017; 17: 638.
  31. Kanamori Y, Kigawa J, Itamochi H, et al.Correlation between loss of PTEN expression andAkt phosphorylation in endometrial carcinoma. ClinCancer Res. 2001; 7: 892-5.